Cramer: Promising data from coronavirus drug trial ‘beginning of the end of the true nightmare’

Investing

Jim Cramer

Scott Mlyn | CNBC

CNBC’s Jim Cramer said Wednesday that positive news from Gilead Sciences about a potential treatment for the coronavirus marked a turning point in the fight against Covid-19.

“What I regard this as is the beginning of the end of the true nightmare, which is that it’s a death sentence,” Cramer said on “Squawk Box.”

U.S. stocks soared on Wednesday after Gilead indicated it was seeing positive, preliminary signs about the effectiveness of its antiviral remdesivir in treating coronavirus patients.

Cramer has been hopeful about remdesivir as a possible treatment.

Last week, the “Mad Money” host said, he believes that scientists testing treatments for the coronavirus will succeed in getting patients “out of the hospital faster” and reducing “death sentence” concerns.

On Thursday, Cramer said at the time, “I do feel better about what Gilead is doing.”

Articles You May Like

Bond losses may offer investors a tax break. Here’s how tax-loss harvesting works
ICE came to town and left behind weakened economies
Three tax votes in November that will affect high earners
Lucid’s Q3 deliveries fall 6.7% as EV maker cuts production to align with demand
Up to 25 million Trump Accounts could be funded by mid-October, IRS CEO Frank Bisignano says

Leave a Reply

Your email address will not be published. Required fields are marked *